Stimulant and hallucinogenic novel psychoactive substances; an update
Fabrizio Schifano, Alessandro Vento, Norbert Scherbaum, Amira Guirguis
Expert Review of Clinical Pharmacology November 2, 2023 DOI: 10.1080/17512433.2023.2279192 via OpenAlex
Summary
AI-generated from the abstractClinicians need regular updates on novel psychoactive substances (NPS) and their acute and long-term medical, psychobiological, and psychopathological risks. Future research should combine pro-drug website analysis with computational chemistry to organize preclinical studies of new psychoactives. Psychedelic research should develop robust study designs to assess potential therapeutic benefits, as these molecules likely have limited dependence liability.
Study at a glance
| Characteristics | Review Peer reviewed |
|---|---|
| Topics | MDMA |
| Keywords | Stimulant Hallucinogen Pharmacology Traditional medicine |
| Citations | 30 |
| Key finding | An integrative research model combining pro-drug website analysis with computational chemistry is needed to organize preclinical studies of novel psychoactives, and psychedelic research requires robust study designs to evaluate therapeutic benefits. |
Abstract
Clinicians should be regularly informed about the range of NPS and their medical, psychobiological and psychopathological risks both in the acute and long term. Future research should focus on an integrative model in which pro-drug websites' analyses are combined with advanced research approaches, including computational chemistry studies so that in vitro and in vivo preclinical studies of index novel psychoactives can be organized. The future of psychedelic research should focus on identifying robust study designs to convincingly assess the potential therapeutic benefits of psychedelics, molecules likely to present with limited dependence liability levels.